Changing State Policy to Promote Stronger Opioid Antagonists: Unnecessary and Potentially Harmful
Law & Policy InsightsSubstance Use Prevention and Harm ReductionHarm Reduction Legal ProjectHarm Reduction Legal Project ResourcesThe increasing need for access to naloxone to reverse opioid-related overdoses has drawn the interest of pharmaceutical companies who see an opportunity to market new, non-generic, more potent opioid antagonist products. State lawmakers have made changes in policy based on these marketing efforts. However, early research suggests that these high dose drugs are unnecessary and pose significant risks and side-effects, raising concerns over the commercialization of harm reduction efforts in the U.S.